08Jul
BIVDA, ABPI and CRUK release briefing on new arrangements for commissioning and funding of six molecular diagnostic tests for cancer
BIVDA, ABPI and CRUK have released a stakeholder briefing to clarify the new arrangements for commissioning and funding of six molecular diagnostic tests for cancer in the NHS in England for 2016/17.
It aims to provide NHS staff – be they commissioner or hospital provider financial staff, clinicians and pathology staff – with a clear understanding how the new funding arrangements for these tests in 2016/17 will operate to support timely and appropriate patient access.
To read the full briefing, click here. For more information, contact BIVDA Chief Executive, Doris-Ann Williams.
Related
Please see below a quote from Doris-Ann Williams, CEO of BIVDA, welcoming the new Secretary of State...
Read More >
BIVDA represents the industry sector who manufacture and distribute diagnostic tests to the NHS. The...
Read More >
Doris-Ann Williams MBE, Chief Executive of the British In Vitro Diagnostics Association (BIVDA), rep...
Read More >
The British In Vitro Diagnostics Association (BIVDA) celebrated its milestone 25th Anniversary on Mo...
Read More >
The 2nd annual UK Diagnostics Summit will take place yet again on November 8th this time at The Stra...
Read More >
PulmoBioMed – a new medtech spin-out in the North East of England Launched with funding f...
Read More >